Loading...
•
Sep 30
Precision BioSciences Q3 2025 Earnings Report
Precision BioSciences reported a net loss of $21.8 million for Q3 2025, with minimal revenue and reduced operating expenses.
Key Takeaways
Precision BioSciences posted a wider net loss in Q3 2025, driven by minimal revenues and continued R&D investment. The company maintains a cash position of over $71 million and anticipates progress on its PBGENE programs into 2026.
Reported a net loss of $21.8 million for Q3 2025.
Revenue for the quarter was only $13,000, reflecting reduced activity under the Novartis agreement.
Cash and cash equivalents stood at $71.2 million, expected to fund operations into 2H 2027.
Advanced dosing in Cohort 3 of the PBGENE-HBV trial; IND filing for PBGENE-DMD anticipated by end of 2025.
Precision BioSciences
Precision BioSciences
Forward Guidance
The company expects to initiate a Phase 1 trial for PBGENE-DMD in 1H 2026 and report data in 2H 2026. Cash runway is expected to extend into 2H 2027, supporting milestone achievements.
Positive Outlook
- PBGENE-HBV trial advanced with Cohort 3 dosing completed.
- Late-breaking presentation accepted at Liver Meeting 2025.
- PBGENE-DMD preclinical data shows durable muscle function improvement.
- IND filing for PBGENE-DMD expected by end of 2025.
- Expected cash runway through 2H 2027 supports upcoming clinical programs.
Challenges Ahead
- Revenue declined significantly year-over-year.
- Company remains in a loss-making position with net loss of $21.8 million.
- Ongoing R&D expenses continue to pressure profitability.
- Program PBGENE-3243 remains paused.
- Heavy reliance on future clinical trial outcomes and regulatory approvals.